Nov 5, 4:08 PM ET
Tandem Diabetes Care reported third-quarter 2026 results for the period ended September 30, 2026, with worldwide sales up 14% to $283.7 million and a net loss of $7.1 million, compared with $21.2 million a year earlier. The company reaffirmed its full-year 2026 guidance, including sales of approximately $1.065 billion to $1.085 billion.
- Worldwide sales rose 14% to $283.7 million; U.S. sales rose 9% to $191.0 million and international sales rose 26% to $92.6 million.
- Gross margin was 57%, compared with 54% in the third quarter of 2025.
- Operating loss was $2.4 million, compared with $22.9 million a year earlier; adjusted EBITDA was $18.0 million.
- For 2026, the company reaffirmed sales guidance of $1.065 billion to $1.085 billion and adjusted EBITDA margin guidance of 5% to 6%.
Read the filing on SEC.gov ↗
Aug 6, 4:08 PM ET
Tandem Diabetes Care reported second quarter 2026 sales of $254.6 million, up 6% from $240.7 million a year earlier, with gross margin of 57% versus 52%. GAAP net loss narrowed to $21.2 million from $52.4 million, and the company reaffirmed its full-year 2026 sales guidance, which matters to shareholders because it shows revenue growth and lower losses while the company updated only its non-cash expense outlook.
- Worldwide sales of $254.6 million, including $179.3 million in the U.S., up 5% in the U.S. and 7% internationally
- GAAP net loss of $21.2 million, compared with $52.4 million in the second quarter 2025, which included a $20.0 million litigation settlement expense
- Full-year 2026 sales guidance reaffirmed at approximately $1.065 billion to $1.085 billion
- Non-cash charges guidance lowered to approximately $85 million from $100 million
Read the filing on SEC.gov ↗
May 21, 4:10 PM ET
At its May 20, 2026 annual meeting, Tandem Diabetes Care stockholders approved charter amendments that allow removal of directors with or without cause and limit officer liability, and approved a 3,260,000-share increase to the 2023 Long-Term Incentive Plan. The company filed the amended charter with Delaware on May 21, 2026, and all nine director nominees were elected, though director Christopher Twomey received 7,034,208 against votes, far more than other nominees.
- Stockholders approved the Section 141(k) amendment allowing director removal with or without cause, with 57,818,029 for and 126,025 against.
- Officer exculpation amendment passed with 45,926,405 for and 9,043,831 against.
- The 2023 Long-Term Incentive Plan increase of 3,260,000 shares was approved with 53,846,696 for and 1,108,529 against.
- Amended charter was filed with Delaware on May 21, 2026.
Read the filing on SEC.gov ↗
May 15, 7:59 AM ET
Tandem Diabetes Care said on May 11, 2026 that it notified Executive Vice President and Chief Commercial Officer Mark Novara that his employment is being terminated without cause, with his last day scheduled for May 18, 2026. The company said its strategy and 2026 goals remain unchanged, and the filing gives no successor or financial terms.
- Mark Novara, EVP and Chief Commercial Officer, notified May 11, 2026
- Termination is without cause; last day scheduled for May 18, 2026
- Company states its strategy and 2026 goals remain unchanged
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.